- Report
- June 2023
- 186 Pages
Global
From €5317EUR$5,500USD£4,567GBP
- Report
- September 2023
- 149 Pages
Global
From €2416EUR$2,499USD£2,075GBP
- Report
- April 2024
- 185 Pages
Global
From €4737EUR$4,900USD£4,069GBP
- Report
- June 2022
- 257 Pages
Global
From €5076EUR$5,250USD£4,360GBP
- Report
- April 2023
- 120 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- October 2019
- 117 Pages
Europe
€4592EUR$4,750USD£3,945GBP
From €115EUR$119USD£99GBP
- Report
- October 2021
- 137 Pages
Global
From €4689EUR$4,850USD£4,028GBP
- Report
- February 2022
- 87 Pages
Global
From €4351EUR$4,500USD£3,737GBP
- Book
- October 2020
- 288 Pages
- Book
- October 2019
- 632 Pages
- Book
- April 2018
- 776 Pages
United States
- Book
- January 2016
- 368 Pages
Thyroid cancer is a type of cancer that affects the thyroid gland, a small organ located in the neck. It is the most common type of endocrine cancer, accounting for around 1-2% of all cancers. Symptoms of thyroid cancer can include a lump in the neck, difficulty swallowing, and hoarseness. Diagnosis is typically made through imaging tests such as ultrasound, CT scan, and MRI. Treatment options include surgery, radiation therapy, and hormone therapy.
The thyroid cancer market is a subset of the larger oncology market. It is a rapidly growing market, driven by increasing prevalence of the disease, technological advancements, and rising awareness. The market is highly competitive, with a number of players offering various treatments.
Some companies in the thyroid cancer market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
